Insulin Delivery Devices Market Outlook 2018-2025: Insulet Corporation, BD, B. Braun Melsungen AG, Medtronic, Tandem Diabetes Care, Eli Lilly and Company, Biocon, Owen Mumford, and Sanofi

The global insulin delivery devices market accounted to US$ 11,869.0 Mn in 2017 and is expected to grow at a CAGR of 8.7% during the forecast period 2018 – 2025, to account to US$ 22,830.0 Mn by 2025.

The rising prevalence of diabetes and rapid growth in the geriatric population are the major factors anticipated to propel the growth for the insulin delivery devices market. However, the high cost of insulin delivery devices is expected to act as major challenges hindering the market growth.

Get PDF sample copy: http://bit.ly/2DeONGt

The increasing rate of obesity, sedentary lifestyle and improper diet play a major role in increasing diabetes among the population worldwide. Physical activity is important to maintain the blood glucose level. Lack of exercise and unhealthy diet such as diet high in fat and calories increase the risk for the development of obesity and diabetes. Obesity is one of the major issue that affect people of all ages and incomes globally. According to World Health Organization (WHO), in 2016, more than 1.9 billion adults aged 18 years and older were overweight. And out of these over 650 million adults were obese. Hence, this is expected to increase the demand of insulin delivery devices in the coming years.

Rise in obesity associated with increasing sedentary lifestyle and improper diet is anticipated to drive the market for insulin delivery devices over the forecast period.

The major players operating in the insulin delivery devices market include BD, B. Braun Melsungen AG, Insulet Corporation, Medtronic, Tandem Diabetes Care, Inc., Eli Lilly and Company, Biocon, Owen Mumford, Ltd., Sanofi among others. The market players are focused towards bringing new and innovative product launches to sustain their position in the market. For instance, in February, 2018, Medtronic launched MiniMed (TM) 670G system for patients with 7-13 years of age.

Buy this report @ http://bit.ly/2DcKCLa

Strategic Insights

Product approvals and agreements were observed as the most adopted strategy in global insulin delivery devices industry. Few of the product approvals and agreements made by the players in the market are listed below;

2018: In June, 2018, Medtronic received CE Mark for its MiniMed(TM) 670G Hybrid Closed Loop System.

2018: In February, 2018, Tandem and Rubin Medical signed an agreement for distribution of insulin pumps in Scandinavia.

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com
Web: https://www.theinsightpartners.com/

This release was published on openPR.